The Evolution of the Competitive Landscape Behind Regeneron's Pleasing Sales of High-dose Treatment for Macular Degeneration, Eylea

Regeneron sees positives in its launch of high-dose Eylea. After gaining FDA approval for its new 8 mg dose of Eylea on Aug. 21, Regeneron racked up $43 million in sales in the United States over the final six weeks of the third quarter for the high-dose regimen, which allows patients to extend injections to once every four months versus once every two months for its original formulation.

Pointedly of the launch, Regeneron CEO Len Schleifer said Thursday during a conference call that its initial sales compare “favorably to recent launches in the retinal disease category.”

Eylea (aflibercept), a recombinant fusion protein, was developed for the treatment of patients with wet age-related macular degeneration (AMD).

A Panoramic View of Eylea’s Top 10 Patent Assignees

According to the Patsnap Bio Sequence Database, the top 10 applicants for the Aflibercept patent are Novartis with 80 applications, Regeneron with 60 applications, and Sanofi with 50 applications. For more applicants, please refer to the image below.

Source, Patsnap Bio

Evolution of the Layout of Top 10 Patent Assignees over the years, the Competitive landscape over time

Exploring the changes occurring within the application structure amongst Aflibercept's top 10 patent assignees over time delivers insights into the competitive landscape's evolution.

Source, Patsnap Bio

How Can You Acquire Comprehensive Information on Aflibercept Sequence Patents for Free?

Firstly, establish a free account with Patsnap Bio Sequence Database. Proceed to the homepage's "standard search" and enter the aflibercept sequence or directly input the drug name, aflibercept, in the "Drug/Gene index.” This single action will unravel extensive details of aflibercept's sequence, patent, literature, data from diversified sources, and a visually competitive landscape of patents.

The left panel's search result details page is equipped with an exhaustive range of filters, enabling you to pinpoint specific data accurately, thereby boosting your search experience and overall efficiency. Clicking on each data point will unfold a rich and detailed data set and a host of advantageous and practical tools to support your research process.

It is important to note that Patsnap Bio is the most extensive sequence search platform for the Patsnap database. It incorporates AI with human-curated data for comprehensive handling of protein and nucleotide sequence data plucked from global patents, biological periodicals, and public repositories. Essential biological sequences are manually annotated, illuminating structural modifications to provide the most accurate sequence data and boost sequence retrieval efficiency.

Free registration is available for the Bio biological sequence database: https://bio.patsnap.com. Act now to expedite your sequence search tasks.